Health

Report on study findings announced in October 2002. [MedScape - Free registration required.]

Manufacturer's site for this selective serotonin and norepinephrine reuptake inhibitor (SSNRI), approved in the US to treat diabetic peripheral neuropathic pain and major depression.

Features information about dosage, usage, warnings, and side effects.